In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.
Baraka, Vito;
Tinto, Halidou;
Valea, Innocent;
Fitzhenry, Robert;
Delgado-Ratto, Christopher;
Mbonye, Martin K;
Van Overmeir, Chantal;
Rosanas-Urgell, Anna;
Van Geertruyden, Jean-Pierre;
D'Alessandro, Umberto;
+1 more...Erhart, Annette;
(2014)
In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.
Antimicrobial agents and chemotherapy, 59 (1).
pp. 734-737.
ISSN 0066-4804
DOI: https://doi.org/10.1128/AAC.03647-14
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high.
